Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 18/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7007275 | 0.84 | CRHR1 (0.55) | CRHR1ALOX15TSHRHSD17B10 | |
| SCHEMBL7009295 | 0.81 | CRHR1 (0.44) | CRHR1ALDH1A1CYP3A4HPGDALOX15 | |
| SCHEMBL7004989 | 0.77 | GAA (0.33) | CRHR1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL7010054 | 0.76 | CDK5 (0.33) | CRHR1 | |
| SCHEMBL7006813 | 0.72 | CRHR1 (0.53) | CRHR1 | |
| SCHEMBL7471870 | 0.70 | CRHR1 (0.76) | CRHR1 | |
| SCHEMBL7219775 | 0.70 | CRHR1 (0.48) | CRHR1 | |
| SCHEMBL7007327 | 0.69 | CRHR1 (0.49) | CRHR1 | |
| SCHEMBL7006275 | 0.69 | LMNA (0.35) | CRHR1KDM4EALDH1A1 | |
| SCHEMBL7004385 | 0.69 | MAPT (0.37) | CRHR1KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1086103-B1 | PYRIDO 2,3-B]INDOLIZINE DERIVATIVES AND AZA ANALOGUES THEREOF; CRF 1 SPECIFIC LIGANDS | NEUROGEN CORP (US) | 2003-05-02 | — | — | EP | claimed |
| US-6495686-B2 | THERAPY FOR PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2002-12-17 | — | — | US | claimed |
| US-20020019525-A1 | Pyrido [2,3-b] indolizine derivatives and aza analogues thereof; CRF1 specific ligands | NEUROGEN | 2002-02-14 | — | — | US | claimed |
| EP-1086103-B1 | PYRIDO 2,3-B]INDOLIZINE DERIVATIVES AND AZA ANALOGUES THEREOF; CRF 1 SPECIFIC LIGANDS | NEUROGEN CORP (US) | 2003-05-02 | — | — | EP | disclosed |
| US-6495686-B2 | THERAPY FOR PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2002-12-17 | — | — | US | disclosed |
| US-20020019525-A1 | Pyrido [2,3-b] indolizine derivatives and aza analogues thereof; CRF1 specific ligands | NEUROGEN | 2002-02-14 | — | — | US | disclosed |
| US-6194574-B1 | SELECTIVELY BIND TO CORTICOTROPIN-RELEASING FACTOR (CRF1) RECEPTORS; FOR TREATING STRESS RELATED DISORDERS SUCH AS POST TRAUMATIC STRESS DISORDER (PTSD) AS WELL AS DEPRESSION, HEADACHE AND ANXIETY | NEUROGEN CORPORATION | 2001-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019525-A1 | Pyrido [2,3-b] indolizine derivatives and aza analogues thereof; CRF1 specific ligands | CRHR1, HTR1D, HTR5A | CRHR1 1/4885KDM4E 3006/4885ALDH1A1 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.